Methods of administering compositions comprising docosapentaenoic acid
A technology of docosapentaenoic acid and docosahexaenoic acid, which is applied in the direction of drug combination, active ingredients of heterocyclic compounds, preservation of fatty substances by additives, etc., and can solve problems such as unmet medical needs
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0139] Intermediates MEGAPEX E90D00EE (90% EPA ethyl ester) and MAXOMEGA DPA95FFA (≥95% DPA synthetic fatty acid made from EPA ethyl ester concentrate) converted to ethyl esters respectively by mixing and homogenizing in a ratio of 98:2 To prepare the composition of the present invention. These intermediates are prepared and sold commercially by Chemport Korea (MEGAPEX) and Equateq Ltd (MAXOMEGA) from Scotland, UK. The relative amounts of fatty acids present in the starting intermediates and the resulting novel compositions are listed in Table 1 below. The resulting novel composition comprises 89.10% EPA, 1.95% DPA, 0.19% HPA, 91.24% omega-3-pentaenoic acid, less than 0.01% DHA, 91.24% omega-3-pentaenoic acid, 93.09% of total omega-3 fatty acids, 3.15% ARA and 3.57% omega-6 fatty acids (all area %).
[0140] Table 1. The intermediate of embodiment 1 and the fatty acid composition (area %) of novel composition
[0141]
Embodiment 2
[0143] Intermediates MEGAPEX E90D00EE (90% EPA ethyl ester) and MAXOMEGA DPA95FFA (≥95% DPA synthetic fatty acid made from EPA ethyl ester concentrate) converted to ethyl esters respectively by mixing and homogenizing in a ratio of 96:4 To prepare the composition of the present invention. These intermediates are prepared and sold commercially by Chemport Korea (MEGAPEX) and Equateq Ltd (MAXOMEGA) from Scotland, UK. The relative amounts of fatty acids present in the starting intermediates and the resulting novel compositions are listed in Table 2 below. The resulting novel composition contained 87.28% EPA, 3.89% DPA, 0.18% HPA, 91.35% omega-3-pentaenoic acid, less than 0.01% DHA, 93.17% total omega-3 fatty acids, and 3.49% omega -6 fatty acids (both area %).
[0144] Table 2. The intermediate of embodiment 2 and the fatty acid composition (area %) of novel composition
[0145]
Embodiment 3
[0147] Intermediates MEGAPEX E90D00EE (90% EPA ethyl ester) and MAXOMEGA DPA95FFA (≥95% DPA synthetic fatty acid made from EPA ethyl ester concentrate) converted to ethyl esters respectively by mixing and homogenizing in a ratio of 94:6 To prepare the composition of the present invention. These intermediates are prepared and sold commercially by Chemport Korea (MEGAPEX) and Equateq Ltd (MAXOMEGA) from Scotland, UK. The relative amounts of fatty acids present in the starting intermediates and the resulting novel compositions are listed in Table 3 below. The resulting novel composition contained 85.46% EPA, 5.84% DPA, 0.18% HPA, 91.48% omega-3-pentaenoic acid, less than 0.01% DHA, 93.26% total omega-3 fatty acids, 3.02% ARA and 3.42% omega-6 fatty acids (both area %).
[0148] Table 3. The intermediate of embodiment 3 and the fatty acid composition (area %) of novel composition
[0149]
PUM
| Property | Measurement | Unit |
|---|---|---|
| Body mass index | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More